AbbVie to Add Liver Warning on Hep C Drugs
October 23, 2015
FDA warns of deadly liver damage with AbbVie hepatitis drugs
By Matthew Perrone
WASHINGTON (AP) — Federal health officials are warning doctors and patients that two hepatitis C drugs from AbbVie can cause life-threatening liver injury in patients with advanced forms of the disease.
The Food and Drug Administration said Thursday it will require AbbVie to add new warnings to Viekira Pak and Technivie after reported deaths and liver transplants in patients who already had liver damage caused by hepatitis C.
Continue reading this entire article:
Coverage Restrictions for Hepatitis C Drugs
Protein Consumption for a Healthy Thanksgiving